Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 17/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1439584 | 0.99 | S1PR5 (0.54) | S1PR5S1PR1ARHPGDSMN1; SMN2 | |
| SCHEMBL1439831 | 0.95 | S1PR5 (0.54) | S1PR5S1PR1 | |
| Hydrochloric Acid SCHEMBL1438121 | 0.94 | S1PR5 (0.54) | S1PR5S1PR1 | |
| SCHEMBL1438369 | 0.94 | S1PR5 (0.58) | S1PR5S1PR1 | |
| Hydrochloric Acid SCHEMBL1438347 | 0.93 | S1PR5 (0.59) | S1PR5S1PR1 | |
| SCHEMBL1438467 | 0.91 | S1PR5 (0.57) | S1PR5S1PR1HPGDSMN1; SMN2NPSR1 | |
| SCHEMBL1438393 | 0.91 | S1PR5 (0.44) | S1PR5S1PR1ARHPGDSMN1; SMN2 | |
| SCHEMBL1440057 | 0.91 | S1PR5 (0.53) | S1PR5S1PR1 | |
| SCHEMBL1439781 | 0.91 | S1PR5 (0.58) | S1PR5S1PR1 | |
| SCHEMBL1439063 | 0.91 | S1PR5 (0.56) | S1PR5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045441-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2015-06-02 | — | — | US | claimed |
| EP-2473490-B1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | claimed |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2012-08-30 | — | — | US | claimed |
| EP-2473490-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | Abbott Healthcare Products B.V. (NL) | 2012-07-11 | — | — | EP | claimed |
| CN-102548976-A | (Thio) morpholine derivatives as S1P modulators | ABBOTT HEALTHCARE PRODUCTS BV | 2012-07-04 | — | — | CN | claimed |
| WO-2011023795-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-03-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | S1PR5 5/4885S1PR1 2/4885AR 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.